The phase II clinical trial of TO-O-1002 approved by the Central Research Ethics Committee (CREC) in Thailand on 11 Aug 2022.
Aug 11, 2022 TO-O-1002 eye drops (NCT05390840) as the company second leading clinical project has been approved by the Central Research Ethics Committee (CREC) in Thailand for treating patients with wet age-related macular degeneration (AMD). TO-O-1002 contained an approved active component in patented eye drop formulation specifically designed for effective drug delivery to the posterior segment of eye. The first patient is planned to be dosed in Q3 of this year.
The global wet AMD market is expected to generate revenue worth $10.5 billion in 2025, registering a CAGR of 11.96% during 2019–2025.